Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation

A cross-sectional analysis of a multicenter outpatient registry

Tomohiko Ono, Nobuhiro Ikemura, Takehiro Kimura, Ikuko Ueda, Hiroaki Tanaka, Hanako Tokuda, Noriyuki Yajima, Keisuke Matsumura, Masahiro Suzuki, Keiichi Fukuda, Shun Kosaka, Seiji Takatsuki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been widely used to prevent stroke in non-valvular atrial fibrillation (NVAF) patients. Stringent monitoring is not required for NOACs, albeit dose adjustments are needed based on specific patient factors, such as renal function, body weight and age, or concomitant medications. We investigated the NOAC dosing patterns and evaluated the predictors of the non-standardized dose reduction (NSDR). Methods: A total of 2452 newly diagnosed NVAF patients were consecutively recruited from secondary- and tertiary-care hospitals between 2012 and 2017. The NOAC doses were classified as one of three: (1) full dose; (2) standardized dose reduction (SDR); or (3) NSDR, consistent with Japanese package inserts. Results: Overall, 66.8% (N = 1637) of the NVAF patients (median age: 69 years, interquartile range [IQR]: 60–76; 70% male; median CHA2DS2-VASc score of 2, IQR: 1–3) received NOACs. NOAC use dramatically increased during the study period (51.2% in 2012–13 to 74.4% in 2016–17). The percentages of SDR and NSDR were 19.6% and 14.4%, respectively; a proportion of SDR and NSDR did not alter drastically. Older age, concomitant antiplatelet therapy, impaired renal function, and prior heart failure or left ventricular dysfunction were independently associated with NSDR. Of note, patients with a high risk (CHA2DS2-VASc score ≥2) had the highest proportion of NSDRs. Conclusions: Nearly half of the NOAC dose reductions in our registry were deemed “non-standardized,” which were seen mostly in patients at significant risk for ischemic stroke. The physician's apprehension regarding excessive bleeding under NOAC use should be appropriately balanced with concern for an increased risk of embolic events.

Original languageEnglish
JournalJournal of Cardiology
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Anticoagulants
Atrial Fibrillation
Registries
Outpatients
Cross-Sectional Studies
Stroke
Product Labeling
Kidney
Secondary Care
Left Ventricular Dysfunction
Tertiary Healthcare
Tertiary Care Centers
Heart Failure
Body Weight
Hemorrhage
Physicians

Keywords

  • Atrial fibrillation
  • Non-vitamin K antagonist oral anticoagulant

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation : A cross-sectional analysis of a multicenter outpatient registry. / Ono, Tomohiko; Ikemura, Nobuhiro; Kimura, Takehiro; Ueda, Ikuko; Tanaka, Hiroaki; Tokuda, Hanako; Yajima, Noriyuki; Matsumura, Keisuke; Suzuki, Masahiro; Fukuda, Keiichi; Kosaka, Shun; Takatsuki, Seiji.

In: Journal of Cardiology, 01.01.2018.

Research output: Contribution to journalArticle

Ono, Tomohiko ; Ikemura, Nobuhiro ; Kimura, Takehiro ; Ueda, Ikuko ; Tanaka, Hiroaki ; Tokuda, Hanako ; Yajima, Noriyuki ; Matsumura, Keisuke ; Suzuki, Masahiro ; Fukuda, Keiichi ; Kosaka, Shun ; Takatsuki, Seiji. / Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation : A cross-sectional analysis of a multicenter outpatient registry. In: Journal of Cardiology. 2018.
@article{9d401c79a25140b997ec97352e6ebddb,
title = "Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter outpatient registry",
abstract = "Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been widely used to prevent stroke in non-valvular atrial fibrillation (NVAF) patients. Stringent monitoring is not required for NOACs, albeit dose adjustments are needed based on specific patient factors, such as renal function, body weight and age, or concomitant medications. We investigated the NOAC dosing patterns and evaluated the predictors of the non-standardized dose reduction (NSDR). Methods: A total of 2452 newly diagnosed NVAF patients were consecutively recruited from secondary- and tertiary-care hospitals between 2012 and 2017. The NOAC doses were classified as one of three: (1) full dose; (2) standardized dose reduction (SDR); or (3) NSDR, consistent with Japanese package inserts. Results: Overall, 66.8{\%} (N = 1637) of the NVAF patients (median age: 69 years, interquartile range [IQR]: 60–76; 70{\%} male; median CHA2DS2-VASc score of 2, IQR: 1–3) received NOACs. NOAC use dramatically increased during the study period (51.2{\%} in 2012–13 to 74.4{\%} in 2016–17). The percentages of SDR and NSDR were 19.6{\%} and 14.4{\%}, respectively; a proportion of SDR and NSDR did not alter drastically. Older age, concomitant antiplatelet therapy, impaired renal function, and prior heart failure or left ventricular dysfunction were independently associated with NSDR. Of note, patients with a high risk (CHA2DS2-VASc score ≥2) had the highest proportion of NSDRs. Conclusions: Nearly half of the NOAC dose reductions in our registry were deemed “non-standardized,” which were seen mostly in patients at significant risk for ischemic stroke. The physician's apprehension regarding excessive bleeding under NOAC use should be appropriately balanced with concern for an increased risk of embolic events.",
keywords = "Atrial fibrillation, Non-vitamin K antagonist oral anticoagulant",
author = "Tomohiko Ono and Nobuhiro Ikemura and Takehiro Kimura and Ikuko Ueda and Hiroaki Tanaka and Hanako Tokuda and Noriyuki Yajima and Keisuke Matsumura and Masahiro Suzuki and Keiichi Fukuda and Shun Kosaka and Seiji Takatsuki",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jjcc.2018.09.003",
language = "English",
journal = "Journal of cardiography. Supplement",
issn = "0914-5087",
publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",

}

TY - JOUR

T1 - Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation

T2 - A cross-sectional analysis of a multicenter outpatient registry

AU - Ono, Tomohiko

AU - Ikemura, Nobuhiro

AU - Kimura, Takehiro

AU - Ueda, Ikuko

AU - Tanaka, Hiroaki

AU - Tokuda, Hanako

AU - Yajima, Noriyuki

AU - Matsumura, Keisuke

AU - Suzuki, Masahiro

AU - Fukuda, Keiichi

AU - Kosaka, Shun

AU - Takatsuki, Seiji

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been widely used to prevent stroke in non-valvular atrial fibrillation (NVAF) patients. Stringent monitoring is not required for NOACs, albeit dose adjustments are needed based on specific patient factors, such as renal function, body weight and age, or concomitant medications. We investigated the NOAC dosing patterns and evaluated the predictors of the non-standardized dose reduction (NSDR). Methods: A total of 2452 newly diagnosed NVAF patients were consecutively recruited from secondary- and tertiary-care hospitals between 2012 and 2017. The NOAC doses were classified as one of three: (1) full dose; (2) standardized dose reduction (SDR); or (3) NSDR, consistent with Japanese package inserts. Results: Overall, 66.8% (N = 1637) of the NVAF patients (median age: 69 years, interquartile range [IQR]: 60–76; 70% male; median CHA2DS2-VASc score of 2, IQR: 1–3) received NOACs. NOAC use dramatically increased during the study period (51.2% in 2012–13 to 74.4% in 2016–17). The percentages of SDR and NSDR were 19.6% and 14.4%, respectively; a proportion of SDR and NSDR did not alter drastically. Older age, concomitant antiplatelet therapy, impaired renal function, and prior heart failure or left ventricular dysfunction were independently associated with NSDR. Of note, patients with a high risk (CHA2DS2-VASc score ≥2) had the highest proportion of NSDRs. Conclusions: Nearly half of the NOAC dose reductions in our registry were deemed “non-standardized,” which were seen mostly in patients at significant risk for ischemic stroke. The physician's apprehension regarding excessive bleeding under NOAC use should be appropriately balanced with concern for an increased risk of embolic events.

AB - Background: Non-vitamin K antagonist oral anticoagulants (NOACs) have been widely used to prevent stroke in non-valvular atrial fibrillation (NVAF) patients. Stringent monitoring is not required for NOACs, albeit dose adjustments are needed based on specific patient factors, such as renal function, body weight and age, or concomitant medications. We investigated the NOAC dosing patterns and evaluated the predictors of the non-standardized dose reduction (NSDR). Methods: A total of 2452 newly diagnosed NVAF patients were consecutively recruited from secondary- and tertiary-care hospitals between 2012 and 2017. The NOAC doses were classified as one of three: (1) full dose; (2) standardized dose reduction (SDR); or (3) NSDR, consistent with Japanese package inserts. Results: Overall, 66.8% (N = 1637) of the NVAF patients (median age: 69 years, interquartile range [IQR]: 60–76; 70% male; median CHA2DS2-VASc score of 2, IQR: 1–3) received NOACs. NOAC use dramatically increased during the study period (51.2% in 2012–13 to 74.4% in 2016–17). The percentages of SDR and NSDR were 19.6% and 14.4%, respectively; a proportion of SDR and NSDR did not alter drastically. Older age, concomitant antiplatelet therapy, impaired renal function, and prior heart failure or left ventricular dysfunction were independently associated with NSDR. Of note, patients with a high risk (CHA2DS2-VASc score ≥2) had the highest proportion of NSDRs. Conclusions: Nearly half of the NOAC dose reductions in our registry were deemed “non-standardized,” which were seen mostly in patients at significant risk for ischemic stroke. The physician's apprehension regarding excessive bleeding under NOAC use should be appropriately balanced with concern for an increased risk of embolic events.

KW - Atrial fibrillation

KW - Non-vitamin K antagonist oral anticoagulant

UR - http://www.scopus.com/inward/record.url?scp=85055568341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055568341&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2018.09.003

DO - 10.1016/j.jjcc.2018.09.003

M3 - Article

JO - Journal of cardiography. Supplement

JF - Journal of cardiography. Supplement

SN - 0914-5087

ER -